Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript

Biotricity, Inc. reported a transformative fiscal year 2025, highlighted by a 16.5% year-over-year revenue increase to $3.7 million in Q4 and a full-year revenue of $13.8 million. The company achieved positive adjusted EBITDA of $438,000 in Q4, signaling a significant step towards profitability, driven by substantial gross margin expansion to 80.4% and a 24.5% reduction in annual operating expenses. Strategic advancements, including the expansion of its AI cardiac platform, new partnerships with three major GPOs providing access to 90% of U.S. hospitals, and international regulatory approvals in Canada and Saudi Arabia, position Biotricity for continued market penetration and growth in the cardiac monitoring and health technology sectors.

Analysis

Biotricity's fiscal year 2025 results signal a critical inflection point, as the company achieved positive adjusted EBITDA of $438,000 in the fourth quarter, positioning it on a clear path to profitability. This was driven by a combination of robust top-line growth and disciplined cost management. Q4 revenue increased 16.5% year-over-year to $3.7 million, contributing to a full-year revenue of $13.8 million, up 14.3%. More significantly, gross margin expanded by 890 basis points in the quarter to 80.4%, reflecting increasing economies of scale, a higher mix of recurring technology fees, and AI-driven operational efficiencies. Concurrently, the company demonstrated strong fiscal discipline, reducing full-year operating expenses by 24.5% and achieving positive operating cash flow for the third consecutive quarter. Strategically, Biotricity has established significant long-term growth vectors through partnerships with three major GPOs, granting access to approximately 90% of U.S. hospitals. However, management has prudently cautioned that these contracts involve long sales and rollout cycles. International expansion into Canada and Saudi Arabia, alongside the launch of a direct-to-consumer service, provide additional, albeit nascent, revenue opportunities. The company's 1-trillion-heartbeat data lake is currently leveraged for internal optimization, with direct monetization being a longer-term goal pending further investment.

Key Decisions for Investors

• Investors should recognize the company's successful pivot to profitable growth, but temper near-term revenue expectations from the new GPO partnerships given the explicitly stated long sales cycles.
• The key metric to monitor will be the conversion of GPO access into tangible contracts; announcements of pilot program wins and subsequent rollouts in the coming quarters will be the primary catalyst for the stock.
• Consider the potential for margin expansion to continue, as management cites achieving economies of scale where new device additions have a lower marginal cost, potentially accelerating the path to net income profitability.
• While the core cardiac monitoring business is strengthening, the direct monetization of its vast data lake and the success of the new direct-to-consumer 'HeartSecure' service represent long-term call options that are not yet central to the current valuation.